Evidence map›Paper›PMID 33893482›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Supporting Drug Development for Neglected Tropical Diseases Using Mathematical Modeling.

Martin Walker, Jonathan I D Hamley, Philip Milton, Frédéric Monnot, Sally Kinrade, Sabine Specht, Bélen Pedrique, Maria-Gloria Basáñez

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Martin WalkerDepartment of Pathobiology and Population Sciences and London Centre for Neglected Tropical Disease Research, Royal Veterinary College, Hatfield, United Kingdom.
Jonathan I D HamleyMRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology and London Centre for Neglected Tropical Disease Research, Imperial College London, London, United Kingdom.
Philip MiltonMRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology and London Centre for Neglected Tropical Disease Research, Imperial College London, London, United Kingdom.
Frédéric MonnotDrugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.
Sally KinradeMedicines Development for Global Health, Melbourne, Victoria, Australia.
Sabine SpechtDrugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.
Bélen PedriqueDrugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.
Maria-Gloria BasáñezMRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology and London Centre for Neglected Tropical Disease Research, Imperial College London, London, United Kingdom.

Funding

Bill and Melinda Gates Foundation OPP 1184344European UnionMedical Research Council MR/R015600/1UK Department for International Development
6 · The paper itself

Abstract

Drug-based interventions are at the heart of global efforts to reach elimination as a public health problem (trachoma, soil-transmitted helminthiases, schistosomiasis, lymphatic filariasis) or elimination of transmission (onchocerciasis) for 5 of the most prevalent neglected tropical diseases tackled via the World Health Organization preventive chemotherapy strategy. While for some of these diseases there is optimism that currently available drugs will be sufficient to achieve the proposed elimination goals, for others-particularly onchocerciasis-there is a growing consensus that novel therapeutic options will be needed. Since in this area no high return of investment is possible, minimizing wasted money and resources is essential. Here, we use illustrative results to show how mathematical modeling can guide the drug development pathway, yielding resource-saving and efficiency payoffs, from the refinement of target product profiles and intended context of use to the design of clinical trials.

Indexed as

OnchocerciasisSchistosomiasisTropical MedicineDrug DevelopmentHumansNeglected Diseasesdrug developmentfilariasesmathematical modelingneglected tropical diseasesonchocerciasis

Identifiers

PMID33893482
PMCPMC8442785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.